Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Robert A. Van Tassel is active.

Publication


Featured researches published by Robert A. Van Tassel.


American Journal of Cardiology | 1990

Percutaneous transluminal coronary angioplasty in the setting of large intracoronary thrombi.

Michael Mooney; Jodi Fishman Mooney; Irvin F. Goldenberg; Adrian K. Almquist; Robert A. Van Tassel

A cohort of 112 consecutive patients with angiographically defined intracoronary thrombi was treated with percutaneous transluminal coronary angioplasty and followed prospectively to determine early and late outcomes. Coronary angioplasty using a treatment modality of intravenous and intracoronary heparin, antiplatelet agents and prolonged inflations with oversized balloons (balloon:vessel ratio, 1.2:1) resulted in clinical success in 103 patients (92%) at hospital discharge. No periprocedural thrombolytic therapy was used and prolonged pretreatment with heparin was not routinely used. Four patients (3.5%) required elective coronary bypass surgery, and 4 patients (3.5%) required emergency coronary artery bypass grafting because of abrupt closure. Late clinical follow-up (mean 7 months) was available in 99 of the 103 successfully treated patients (96%). Seventy-three percent of patients were asymptomatic at follow-up, and 27% had class I or II angina. No patients had a late myocardial infarction. Elective coronary artery bypass surgery was required in 3 patients (3%) and repeat coronary angioplasty in 17 patients (17%). There were 2 late cardiac deaths at 7 months. Ninety-four patients (95%) had an event free follow-up defined as absence of coronary artery bypass surgery, myocardial infarction or death. In conclusion, coronary angioplasty alone, using intracoronary heparin and prolonged balloon inflations with relatively oversized balloons may be helpful to achieve a high initial success rate, low incidence of in-hospital complications and excellent long-term results in patients with intracoronary thrombus.


Jacc-cardiovascular Interventions | 2010

Left atrial appendage obliteration: mechanisms of healing and intracardiac integration.

Robert S. Schwartz; David R. Holmes; Robert A. Van Tassel; Robert G. Hauser; Timothy D. Henry; Michael Mooney; Ray V. Matthews; Shephal K. Doshi; Russell M. Jones; Renu Virmani

OBJECTIVES The objectives of this study were: 1) to delineate the temporal course of histopathologic healing as the left atrial appendage (LAA) is obliterated by a mechanical device; and 2) to compare this process with other intravascular and intracardiac implanted technologies. BACKGROUND Intracardiac device healing is incompletely understood. We thus studied the histopathology of device-based LAA obliteration. METHODS Nine dog hearts were examined over time after LAA device placement and results were compared with human hearts with prior LAA obliteration using the same device. RESULTS At 3 days in dogs, atrial surfaces were covered by fibrin, which sealed gaps between the LA wall and the device and filled the LA appendage cavity. At 45 days, endothelial cells covered the endocardial surface with underlying smooth muscle cells that sealed the device-LA interface. Regions with prior thrombus were replaced by endocardium surrounding the device membrane. Disorganized thrombus remained in the LAA body and at the periphery near the appendage walls. Mild inflammation was observed as thrombus resorbed. By 90 days, a complete endocardial lining covered the former LAA ostium. Organizing thrombus had become connective tissue, with no residual inflammation. The human necropsy hearts had similar findings. In these 4 hearts (139, 200, 480, and 852 days after implant), the ostial fabric membrane was covered with endocardium. The appendage surface contained organizing thrombus with minimal inflammation. Organizing fibrous tissue was inside the LAA cavity, prominent near the atrial wall. The LAA interior contained organizing thrombus. CONCLUSIONS This intracardiac device integration study delineated healing stages of early thrombus deposition, thrombus organization, inflammation and granulation tissue, final healing by connective tissue, and endocardialization without inflammation. These observations may yield insight into cellular healing processes in other cardiac devices.


Catheterization and Cardiovascular Interventions | 2006

Radiation following percutaneous balloon aortic valvuloplasty to prevent restenosis (RADAR pilot trial)

Wes R. Pedersen; Robert A. Van Tassel; Talia A. Pierce; David M. Pence; David J. Monyak; Tae H. Kim; Kevin M. Harris; Thomas Knickelbine; John R. Lesser; James D. Madison; Michael Mooney; Irvin F. Goldenberg; Terrence F. Longe; Anil Poulose; Kevin J. Graham; Richard R. Nelson; Marc Pritzker; Luis Pagan-Carlo; Charlene R. Boisjolie; Andrey G. Zenovich; Robert S. Schwartz

Objectives: We wished to determine the feasibility and early safety of external beam radiation therapy (EBRT) used following balloon aortic valvuloplasty (BAV) to prevent restenosis. Background: BAV for calcific aortic stenosis (AS) has been largely abandoned because of high restenosis rates, i.e., > 80% at 1 year. Radiation therapy is useful in preventing restenosis following vascular interventions and treating other benign noncardiovascular disorders. Methods: We conducted a 20‐patient, pilot study evaluating EBRT to prevent restenosis following BAV in elderly patients with calcific AS. Total doses ranging from 12–18 Gy were delivered in fractions over a 3–5 day post‐op period to the aortic valve. Echocardiography was performed pre and 2 days post‐op, 1, 6, and 12 months following BAV. Results: One‐year follow‐up is completed (age 89 ± 4). There were no complications related to EBRT. Eight patients died prior to 1 year; 5 of 10 (50%) in the low‐dose (12 Gy) group and 3 of 10 (30%) in the high‐dose (15–18 Gy) group. None of these 8 patients had restenosis, i.e., > 50% loss of the initial AVA gain, and only three deaths were cardiac in origin. One patient underwent aortic valve replacement and none repeated BAV. By 1 year, 3 of the initial 10 (30%) in the low‐dose group and 1 of 9 (11%) in the high‐dose group demonstrated restenosis (21% overall). Conclusions: EBRT following BAV in elderly patients with AS is feasible, free of early complications, and holds promise in reducing the 1 year restenosis rate in a dose‐dependent fashion.


Catheterization and Cardiovascular Interventions | 2009

Is the left atrial appendage more than a simple appendage

Hidehiko Hara; Renu Virmani; David R. Holmes; Maurice Buchbinder; John R. Lesser; Robert A. Van Tassel; Michael Mooney; Robert S. Schwartz

The left atrial appendage (LAA) is a cardiac structure with unique anatomic and functional features. It is significantly more than a simple chamber appended to the left atrium (LA), differing from the LA in structure, function, and hormonal activity. Unfortunately, it is the source of more than 90% of cardiac‐based emboli, particularly in atrial fibrillation, mandating lifelong anticoagulation. Percutaneous LAA exclusion was developed to limit or eliminate cardioembolic events in patients with atrial fibrillation. Benign healing of the appendage occurs without adverse hemodynamic effects, and with no residual surface thrombus or tissue damage. The feasibility of this treatment is now established, suggesting that percutaneous therapy is safe, practical and possibly effective to eliminate the need for anticoagulation and significantly reduce cardioembolic events.


Catheterization and Cardiovascular Interventions | 2007

Feasibility of transcatheter intervention for severe aortic stenosis in patients ≥90 years of age: Aortic valvuloplasty revisited

Wes R. Pedersen; Paul J. Klaassen; Charlene R. Boisjolie; Talia A. Pierce; Kevin M. Harris; John R. Lesser; Hidehiko Hara; Michael Mooney; Kevin J. Graham; Vibhu R. Kshettry; Irvin F. Goldenberg; Marc R. Priztker; Robert A. Van Tassel; Robert S. Schwartz

The goals of this study were to determine the feasibility, safety, and early outcomes of balloon aortic valvuloplasty (BAV) for severe aortic stenosis in a nonagenarian population.


Circulation | 2007

Patent Foramen Ovale Closure by Radiofrequency Thermal Coaptation First Experience in the Porcine Model and Healing Mechanisms Over Time

Hidehiko Hara; Thomas K. Jones; Elena Ladich; Renu Virmani; David C. Auth; Joseph E. Eichinger; Robert J. Sommer; Robert A. Van Tassel; Robert S. Schwartz

Background— Percutaneous transcatheter patent foramen ovale (PFO) closure is now standard practice and may limit embolic complications for at least 10 years. Implantable PFO closure devices may be complicated by thrombosis, infection, device fracture, or embolization. A novel strategy uses radiofrequency-based thermal energy to seal PFO membranes, with no implanted device. We successfully used this method and examined histopathologic events in swine to characterize safety and efficacy. Methods and Results— Thirteen domestic swine were examined over time after thermal PFO closure. Three animals were euthanized within 1 hour of treatment, 5 after 7 days, and 5 at 28 days. Gross and histopathologic findings were examined. Radiofrequency energy was delivered successfully in all cases, and PFOs were closed in 12 of 13 cases. One case was not suitable for histological examination because of laceration at euthanasia, and the other PFO was clinically closed, with no shunt at 7 days, but was histologically open. All of the other PFOs were confirmed closed histologically. Acute histological results showed edema, hemorrhage, and myocyte necrosis. Minimal thrombus formation occurred on the left atrial endocardial surface. At day 7, transmural thermal effects occurred through the atrial wall that extended to the epicardial surface. At day 28, thermal effects showed excellent scar formation. Collagen, matrix, and neovascularization were present in all cases. No animal experienced adverse events. Conclusions— Thermal PFO closure is feasible, safe, and effective in swine. Thermal healing is nearly complete by 4 weeks and consists of collagen formation and tunnel closure. This technique may allow substantial reduction in PFO closure risk over current device-based therapy.


American Journal of Cardiology | 1989

Soft-tipped coronary artery catheters reduce the frequency of coronary artery dissection

Paul R. Van Tassel; Irvin F. Goldenberg; Wes R. Pedersen; Kristin Madison; Constance Madison; David Streitz; Michael Walker; Susanne K. Roeller; S.Murthy Tadavarthy; Philip D. Murray; James E. Finstad; Timothy J. Koelz; Mark Samii; James D. Madison; Marc Pritzker; Fredarick L. Gobel; Robert A. Van Tassel

Abstract Coronary artery dissection is an infrequent, but potentially fatal, complication of coronary arteriography with an incidence ranging from 0.02 to 0.34%. 1–3 Soft-tipped catheters were developed to reduce this risk. In vitro and in vivo studies have suggested that soft-tipped catheters are less traumatic to the arterial wall than conventional catheters. 4,5 To determine the clinical importance of these findings, the incidence of coronary artery dissection associated with both soft-tipped catheters and conventional catheters was compared in a 10-year retrospective study.


Interventional cardiology clinics | 2018

A History of Left Atrial Appendage Occlusion

David R. Holmes; Robert S. Schwartz; George G. Latus; Robert A. Van Tassel

A new era in antiembolic therapy has been initiated by the growing numbers of device-based therapies. Early concerns surrounding eliminating this enigmatic structure have not proven true. Other benefits are being further evaluated. Many other questions remain, such as whether there is a device-specific outcome effect or whether it is a class effect. Other questions include other devices, what head-to-head studies will show, and the impact of residual leak. Left atrial appendage using the Watchman ablation strategy can reduce cardioembolic stroke, with comparable or fewer adverse effects by device technology than obtained by long-term anticoagulation with its attendant bleeding risks.


Circulation | 2008

Response to Letter Regarding Article, “Patent Foramen Ovale Closure by Radiofrequency Thermal Coaptation: First Experience in the Porcine Model and Healing Mechanisms Over Time”

Hidehiko Hara; Robert A. Van Tassel; Robert S. Schwartz; Thomas K. Jones; Elena Ladich; Renu Virmani; David C. Auth; Joseph E. Eichinger; Robert J. Sommer

BACKGROUND Percutaneous transcatheter patent foramen ovale (PFO) closure is now standard practice and may limit embolic complications for at least 10 years. Implantable PFO closure devices may be complicated by thrombosis, infection, device fracture, or embolization. A novel strategy uses radiofrequency-based thermal energy to seal PFO membranes, with no implanted device. We successfully used this method and examined histopathologic events in swine to characterize safety and efficacy. METHODS AND RESULTS Thirteen domestic swine were examined over time after thermal PFO closure. Three animals were euthanized within 1 hour of treatment, 5 after 7 days, and 5 at 28 days. Gross and histopathologic findings were examined. Radiofrequency energy was delivered successfully in all cases, and PFOs were closed in 12 of 13 cases. One case was not suitable for histological examination because of laceration at euthanasia, and the other PFO was clinically closed, with no shunt at 7 days, but was histologically open. All of the other PFOs were confirmed closed histologically. Acute histological results showed edema, hemorrhage, and myocyte necrosis. Minimal thrombus formation occurred on the left atrial endocardial surface. At day 7, transmural thermal effects occurred through the atrial wall that extended to the epicardial surface. At day 28, thermal effects showed excellent scar formation. Collagen, matrix, and neovascularization were present in all cases. No animal experienced adverse events. CONCLUSIONS Thermal PFO closure is feasible, safe, and effective in swine. Thermal healing is nearly complete by 4 weeks and consists of collagen formation and tunnel closure. This technique may allow substantial reduction in PFO closure risk over current device-based therapy.


Archive | 2003

Barrier device for ostium of left atrial appendage

Robert A. Van Tassel; Robert G. Hauser

Collaboration


Dive into the Robert A. Van Tassel's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Michael Mooney

Abbott Northwestern Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

John R. Lesser

Abbott Northwestern Hospital

View shared research outputs
Top Co-Authors

Avatar

Wes R. Pedersen

Abbott Northwestern Hospital

View shared research outputs
Top Co-Authors

Avatar

Renu Virmani

Armed Forces Institute of Pathology

View shared research outputs
Top Co-Authors

Avatar

James D. Madison

Abbott Northwestern Hospital

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge